Endothelial activation and cytokine expression in human acute cardiac allograft rejection

Summary By extrapolation from the responses of cultured human umbilical vein endothelial cells (EC) and bovine aortic EC to short-term cytokine stimulation, EC activation is postulated as a likely component of the host response in acute allograft rejection and cardiac transplant-associated accelerated arteriosclerosis. To investigate the extent to which EC activation occurs in vivo in humans and to identify potential targets for therapeutic interventions, we compared the phenotypic characteristics of vascular EC as seen during clinicopathologically significant vs non-significant acute cardiac allograft rejection. We used monoclonal and monospecific polyclonal antibodies to coagulation molecules [tissue factor, thrombomodulin (TM), antithrombin III (AT-III), fibrinogen/fibrin, cross-linked fibrin and von Willebrand factor (vWF)], adhesion molecules (P-selectin, ICAM-1) and major histocompatibility complex (MHC) class I and II molecules. In addition we sought evidence of local cytokine production (IL-1, IL-2R, IL-4, IL-6, IL-7, IL-8, TNF-α, PDGF-AA, PDGF-BB), which might mediate alterations in expression of these proteins. We found that in clinically significant grades of cardiac allograft rejection requiring increased immunosuppression, in contrast to lesser grades of rejection not requiring clinical intervention, there was increased microvascular EC activation and differential expression of cytokines. EC changes associated with more extensive cardiac allograft rejection requiring treatment included: (i) disruption of the normal anticoagulant state with downregulation of TM and AT-III, upregulation of tissue factor and vWF expression, and associated extensive fibrin deposition; (ii) upregulation of MHC class I antigens, which are potential targets for host cytotoxic T lymphocytes; (iii) increased expression of the leucocyte adhesion molecules P-selectin and ICAM-1; (iv) expression of the proinflammatory cytokines IL-1β and TNF-α; and (v) increased expression of PDGF-AA and BB, which are known to promote migration and proliferation of intimal cells, and hence may contribute to development of transplant-associated atherosclerosis. Collectively these findings suggest that immune events resulting in EC surface changes and/or production of key cytokines play a role in the pathogenesis of acute transplant rejection and may contribute to the long-term complication of accelerated arteriosclerosis in allograft coronary arteries.Abbreviations: AT-III, antithrombin III; ATGAM, anti T cell immunoglobulin; EC, endothelial cells, EMB, endomyocardial biopsies; IL, interleukin; mAbs, monoclonal antibodies; MHC, major histocompatibility complex. protein C; PDGF, platelet-derived growth factor; PECAM, platelet endothelial cellular adhesion molecule; PS, protein S; TM, thrombomodulin; TNF-α, tumor necrosis factor-alpha; vWF, von Willebrand factor; XL, cross linked.

[1]  D. Adams,et al.  CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. , 1994, The American journal of pathology.

[2]  W. Hancock,et al.  Analysis of proliferating cell nuclear antigen expression aids histological diagnosis and is predictive of progression of human cardiac allograft rejection. , 1994, The American journal of pathology.

[3]  M. Odeh Tumor necrosis factor-α as a myocardial depressant substance , 1993 .

[4]  A. Minty,et al.  IL‐4 and IL‐13 exhibit comparable abilities to reduce pyrogen‐induced expression of procoagulant activity in endothelial cells and monocytes , 1993, FEBS Letters.

[5]  P. Tipping,et al.  Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. , 1993, The American journal of pathology.

[6]  Mike D Cadogan,et al.  The distribution of adhesion molecules in human atherosclerosis , 1993, Histopathology.

[7]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[8]  P. Libby,et al.  An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  M. Yacoub,et al.  INDUCTION OF VASCULAR ADHESION MOLECULES DURING REJECTION OF HUMAN CARDIAC ALLOGRAFTS , 1992, Transplantation.

[10]  T. Sablinski,et al.  Blocking of mononuclear cell accumulation, cytokine production, and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy. , 1992, Transplantation.

[11]  W. Hancock,et al.  Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression , 1992, The Journal of experimental medicine.

[12]  E. Arbustini,et al.  Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical and immunoblotting study. , 1991, The American journal of pathology.

[13]  R. Atkins,et al.  TNF as a mediator of cardiac transplant rejection, including effects on the intragraft protein C/protein S/thrombomodulin pathway. , 1991, Transplantation proceedings.

[14]  M. Hammond,et al.  A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. , 1990, The Journal of heart transplantation.

[15]  R. Cotran,et al.  The role of endothelial cells in inflammation. , 1990, Transplantation.

[16]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[17]  C. Hengstenberg,et al.  Immunocytochemical changes suggestive of damage to endothelial cells during rejection of human cardiac allografts. , 1990, Transplantation.

[18]  J. Vilček,et al.  IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. , 1989, Journal of immunology.

[19]  K. Tracey,et al.  Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. , 1994, Annual review of medicine.

[20]  M. Odeh Tumor necrosis factor-alpha as a myocardial depressant substance. , 1993, International journal of cardiology.

[21]  W. Casscells Smooth muscle cell growth factors. , 1991, Progress in growth factor research.

[22]  W. Fiers,et al.  Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.